...
Items | Hierarchy/Topic | EARLY VISIBILITY OF PROPOSED CONTENT CHANGES | Planned Release timing (*this is provisional only and is subject to change) |
---|---|---|---|
1. | Clinical Finding | Update for Concepts Using 'Caused by' Clinical finding concepts containing "Caused by" in their FSN will be reviewed and will be updated (if applicable) according to the editorial guidelines related to causation here. There is one area where work is still in progress:
| 2024 International Release |
2. | Procedure | Update Hierarchy 363680008|Radiographic imaging Procedure (procedure)|and Descendants A Briefing Note documenting the proposed changes for the hierarchy 363680008|Radiographic imaging procedure (procedure)| and descendants was shared with the Editorial Advisory Group, Clinical Leads Group, Member Forum, Content Managers Advisory Group, and other key stakeholders in July 2023. Feedback was received from a wide range of stakeholders. In response to this feedback, the proposed changes to the hierarchy have been modified. These modifications will address issues raised in the feedback. This Informational Briefing Note summarizes the changes that will be implemented. Implementation of the content changes will commence in Q4 2023. The updates will be implemented in sub-hierarchies and promoted over a number of international monthly releases until complete. | Ongoing in phases across 2024 International Releases Please see item 18 below - Mammography and digital breast tomosynthesis |
3. | Content Improvement | Updates to the Inactivation Reason and Historical Association for 'On Examination' and 'Complaining of' Inactive Content Many of the 'on examination' and 'complaining of' concepts were previously inactivated with the inactivation reason of |Moved elsewhere| with a historical association value |Extension Namespace 1000000|. This content will be updated with an inactivation reason of |Non-conformance to editorial policy| and a historical association of |Alternative| to a suitable international concept. | Q2-Q3 2024 International Release |
4. | Social Context | Ethnic/Racial Group Social Context Content Inactivation The subtypes of 372148003 |Ethnic group (ethnic group)| and 415229000 |Racial group (racial group)| will be inactivated as they are out of scope for the International Edition. A briefing note is available here. | In discussion - to be determined |
5. | Clinical Finding/Procedure | Patient/Subject concepts in the Clinical finding and Procedure Hierarchies Concepts in the Clinical finding and Procedure hierarchies that contain the explicit context of patient or subject will be inactivated and replaced with concepts without this explicit context. For further information please see briefing note. | On hold - to be determined |
6. | Procedure | Inactivation of 277132007|Therapeutic procedure (procedure) The concept 277132007 |Therapeutic procedure (procedure) will be inactivated with the inactivation reason of Outdated and a replacement association target of 71388002 |Procedure (procedure)|. The nearly 2000 descendants will be reviewed as to the appropriateness of either the Has intent (attribute) of Therapeutic intent, or a Method (attribute) of Therapy - action. For further information please see briefing note. | Q2 2024 International Release |
7. | Annotation | OWL Axiom Expressions for Annotation Properties The new annotation properties are represented in the OWL expression axiom refset as follows:
These axiom updates are published in the March 2024 International Edition release. The authoring tool has been updated to ensure all new subconcepts of 1295447006 |Annotation attribute (attribute)| are represented as SubAnnotationPropertyOf(). Other tools will be updated to correctly consume the updated syntax. This will be carefully tested and rolled out over the next few months. | Q2 2024 International Release |
8. | Clinical Finding | Inactivation of Mechanical Complication of <x> Device In October 2023 the Editorial Advisory Group made a decision that the concepts that represent a mechanical complication of <x> device are ambiguous. Following this a briefing note was shared with the community of practice to both inform and collect feedback. This feedback has been reviewed and the work will be proceeding. The concepts will be inactivated as ambiguous with a historical association to 473023007 |Complication associated with device (disorder)| or a suitable subtype. | Q2-Q3 2024 International Release |
9. | Procedure | Inactivation of 410770002 |Administration of anesthesia for procedure (procedure)| and Subtypes A Briefing note was presented to Anesthesia CRG with a proposal for review and remodeling of 1263452006 |Anesthesia and/or sedation procedure (procedure)| hierarchy. As part of that proposal, inactivation of 410770002 |Administration of anesthesia for procedure (procedure)| hierarchy was agreed. This inactivation will affect 410770002 |Administration of anesthesia for procedure (procedure)|and subtypes, and 10745231000119102 |Cardiac arrest due to administration of anesthesia for obstetric procedure in pregnancy (disorder)|. Concepts in 410770002 |Administration of anesthesia for procedure (procedure)|hierarchy will be inactivated with Inactivation reason = Outdated component and Replaced by 399097000 |Administration of anesthesia (procedure)|. For 10745231000119102 |Cardiac arrest due to administration of anesthesia for obstetric procedure in pregnancy (disorder)|FSN will be changed to 10745231000119102 |Cardiac arrest due to administration of anesthesia in pregnancy (disorder)| and value for 42752001 |Due to (attribute)| will be changed to 399097000 |Administration of anesthesia (procedure)|. | Q2 2024 International Release |
10. | Dose Forms | Pharmaceutical Dose Forms with Two or More Intended Sites Pharmaceutical Dose Forms with more than one intended site will use “and” in their descriptions and include all intended sites in the model. By representing combinations of intended sites as a conjunction ('and' in the description) this will facilitate searching by end users. The concepts are logically modeled as conjunction. Existing dose forms with "or" will be updated to "and" in their descriptions, this will be included in the Editorial Guide. 9 clinical drugs using these dose forms will correspondingly have their descriptions updated to 'and'. Note - pharmaceutical dose forms with two or more administration methods: | Q2/Q3 2024 International Release |
11. | Clinical Finding | Substance Abuse/Use There has been a shift from the term "substance abuse" to a more nuanced understanding of substance use disorders in this domain which is reflected in both ICD-11 and DSM-5 indicating a greater emphasis on the spectrum of substance-related problems. Several members have expressed the need for content updates to incorporate this change and to simplify the translation process. Consequently, efforts to revise the content associated with 66214007 |Substance abuse (disorder)| will begin and is expected to be completed by the end of Q2. An example of the content structure and terming using opioid use is shown. Specifically, descriptions will be added with “harmful pattern of X substance use” replacing the term “abuse” in the FSN and PT however the “abuse” descriptions are persisted as synonyms to facilitate searching. In most cases there is no change in meaning, therefore the concepts will not be inactivated. Approximately 100 existing concepts relating to “abuse” will be affected together with the addition of new concepts to represent “harmful episode” and the higher level “Disorder caused by X substance”. | Q2 2024 International Release |
12. | Clinical Finding | Inactivation of Complication Disorder Concepts (371 concepts) The inactivation of concepts that reference “complication” without specifying the nature of the complication is planned. The primitive “Complication (disorder)” grouper was inactivated in 2022 due to a lack of consistency or definition of what would properly be assigned as a subtype. The concepts will be inactivated with inactivation reason “Classification derived concept” and replacement by the parent concept. For further information please see this briefing note. | June 2024 International Release |
1413. | Observable Entity/Procedure | Update Role Grouping for Observable Entity and Evaluation Procedure Concepts Currently, Observable Entity concepts’ attributes are self-grouped in the international edition. Based on recommendation by the Modeling Advisory Group (MAG), the policy has changed to group these attributes together in order to support modeling concepts with multiple observations and address inconsistent modeling between evaluation procedures and observable entities. The same changes will be applied to the concepts in the evaluation procedure hierarchy that are modeled with applicable self-grouped attributes. Please see this briefing note for details. | July 2024 International Release |
1614. | Procedure | Angioplasty procedures In response to several enquiries from members about the apparent duplication of concepts and descriptions for procedures representing 'Percutaneous transluminal angioplasty' an analysis of the content in this area is underway. It is expected to result in inactivation of duplicates, updates to the descriptions of published concepts and remodeling to represent the imaging guidance aspect where appropriate. After the analysis of the impact has been completed, a Briefing Note will be dispatched to provide details of the changes. Examples of potential duplication:
| Q3 2024 International Release |
1715. | Substance | Antibody to X Organism The descriptions for the children of 312301006 |Infective organism antibody (substance)| (antibody to X or X antibody) will be updated as per editorial guidelines where applicable. | Q2 2024 International Release |
1816. | Procedure | Update 71651007|Mammography (procedure)| and Descendants As part of the content update being undertaken for: 363680008|Radiographic imaging Procedure (procedure)| and Descendants (please see item 2 above for details) Content changes will be undertaken for 71651007|Mammography (procedure)| and subtypes. A new concept will be added as the supertype - Imaging of breast (procedure). New imaging actions will be added:
These new actions will distinguish mammography from the less specific supertype 278110001 |Radiographic imaging - action (qualifier value)|. 71651007|Mammography (procedure)| and subtypes will be modeled with the new imaging action Mammographic imaging - action (qualifier value) 450566007|Digital tomosynthesis of breast (procedure)| will be sufficiently defined by the new imaging action Mammographic digital tomosynthesis - action (qualifier value) and remain a subtype of 71651007|Mammography (procedure)|. | Q2 2024 International Release |
1917. | Procedure | Review 1263452006 |Anesthesia and/or sedation procedure (procedure)| A review of the 1263452006 |Anesthesia and/or sedation procedure (procedure)| hierarchy is in progress, the focus is on:
| Q2-Q3 2024 International Release |
2018. | Procedure | Review 48537004 |Bypass graft (procedure)| A review of the 48537004 |Bypass graft (procedure)| hierarchy is in progress, the focus is on:
| Q2-Q3 2024 International Release |
2119. | Procedure | Review Use of 424876005 |Surgical approach (attribute)| A review to generalize 424876005 |Surgical approach (attribute)| to allow non-surgical procedures to be modeled with a subtype of <<103379005 |Procedural approach (qualifier value)| is in progress.
| Q2-Q3 2024 International Release |
2220. | Procedure | Review 1287742003 |Radiotherapy (procedure)| A review of 1287742003 |Radiotherapy (procedure)| hierarchy is in progress, the focus is on:
| Q2-Q3 2024 International Release |
2321. | Procedure | Review 424226004 |Using device (attribute)| vs. 363699004 |Direct device (attribute)| for Modeling of Repair Procedures 424226004 |Using device (attribute)| and 363699004 |Direct device (attribute)| are used interchangeably for modeling of repair procedures within the Repair group of relationships.
| Q2-Q3 2024 International Release |
2422. | Medicinal Product | Therapeutic Role Groupers Please see the informational briefing note on Inactivation of Therapeutic Role Groupers in the Medicinal Product Hierarchy here. | Q2-Q3 2024 International Release |
2523. | Morphologic Abnormality | Update << 1187137001|Squamous intraepithelial neoplasia (morphologic abnormality)| The << 1187137001|Squamous intraepithelial neoplasia (morphologic abnormality)| subhierarchy will be updated to properly represent the two common grading systems used globally. For further information please see this briefing note. | June 2024 International Release |
...